Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 1811 entries
Sorted by: Best Match Show Resources per page
GDP versus ESHAP Regimen in Relapsed and/or Refractory Hodgkin lymphoma: A Comparison Study.

International journal of hematology-oncology and stem cell research

Ramzi M, Rezvani A, Dehghani M.
PMID: 25802695
Int J Hematol Oncol Stem Cell Res. 2015 Jan 01;9(1):10-4.

BACKGROUND: Despite multiple published studies reporting result of salvage regimens for relapsed and refractory Hodgkin's lymphoma, there are no comparisons of different combinations.PATIENTS AND METHODS: A Total of 44 patients identified with refractory or relapsed Hodgkin's Lymphoma were considered...

Cite
Ramzi M, Rezvani A, Dehghani M. GDP versus ESHAP Regimen in Relapsed and/or Refractory Hodgkin lymphoma: A Comparison Study. Int J Hematol Oncol Stem Cell Res. 2015;9(1):10-4
Ramzi, M., Rezvani, A., & Dehghani, M. (2015). GDP versus ESHAP Regimen in Relapsed and/or Refractory Hodgkin lymphoma: A Comparison Study. International journal of hematology-oncology and stem cell research, 9(1), 10-4.
Ramzi, Mani, et al. "GDP versus ESHAP Regimen in Relapsed and/or Refractory Hodgkin lymphoma: A Comparison Study." International journal of hematology-oncology and stem cell research vol. 9,1 (2015): 10-4.
Ramzi M, Rezvani A, Dehghani M. GDP versus ESHAP Regimen in Relapsed and/or Refractory Hodgkin lymphoma: A Comparison Study. Int J Hematol Oncol Stem Cell Res. 2015 Jan 01;9(1):10-4. PMID: 25802695; PMCID: PMC4369228.
Copy Download .nbib Format: NLM
Anti-cancer potential of flavonoids: recent trends and future perspectives.

3 Biotech

Batra P, Sharma AK.
PMID: 28324424
3 Biotech. 2013 Dec;3(6):439-459. doi: 10.1007/s13205-013-0117-5. Epub 2013 Feb 12.

Cancer is a major public health concern in both developed and developing countries. Several plant-derived anti-cancer agents including taxol, vinblastine, vincristine, the campothecin derivatives, topotecan, irinotecan and etoposide are in clinical use all over the world. Other promising anti-cancer...

Cite
Batra P, Sharma AK. Anti-cancer potential of flavonoids: recent trends and future perspectives. 3 Biotech. 2013;3(6):439-459doi: 10.1007/s13205-013-0117-5.
Batra, P., & Sharma, A. K. (2013). Anti-cancer potential of flavonoids: recent trends and future perspectives. 3 Biotech, 3(6), 439-459. https://doi.org/10.1007/s13205-013-0117-5
Batra, Priya, and Sharma, Anil K. "Anti-cancer potential of flavonoids: recent trends and future perspectives." 3 Biotech vol. 3,6 (2013): 439-459. doi: https://doi.org/10.1007/s13205-013-0117-5
Batra P, Sharma AK. Anti-cancer potential of flavonoids: recent trends and future perspectives. 3 Biotech. 2013 Dec;3(6):439-459. doi: 10.1007/s13205-013-0117-5. Epub 2013 Feb 12. PMID: 28324424; PMCID: PMC3824783.
Copy Download .nbib Format: NLM
Arteriovenous Fistula Embolization in Suspected Parauterine Choriocarcinoma.

Case reports in obstetrics and gynecology

Alturkistani H, Almarzooqi MK, Oliva V, Gilbert P.
PMID: 27403360
Case Rep Obstet Gynecol. 2016;2016:6353471. doi: 10.1155/2016/6353471. Epub 2016 Jun 14.

This is a case of choriocarcinoma that did not regress after chemotherapy treatment. A 30-year-old female patient (gravida 2, para 2), presented to our ER with stroke and persistent mild pelvic pain 2 months after a Caesarean section. Computed...

Cite
Alturkistani H, Almarzooqi MK, Oliva V, et al. Arteriovenous Fistula Embolization in Suspected Parauterine Choriocarcinoma. Case Rep Obstet Gynecol. 2016;2016:6353471doi: 10.1155/2016/6353471.
Alturkistani, H., Almarzooqi, M. K., Oliva, V., & Gilbert, P. (2016). Arteriovenous Fistula Embolization in Suspected Parauterine Choriocarcinoma. Case reports in obstetrics and gynecology, 20166353471. https://doi.org/10.1155/2016/6353471
Alturkistani, Husain, et al. "Arteriovenous Fistula Embolization in Suspected Parauterine Choriocarcinoma." Case reports in obstetrics and gynecology vol. 2016 (2016): 6353471. doi: https://doi.org/10.1155/2016/6353471
Alturkistani H, Almarzooqi MK, Oliva V, Gilbert P. Arteriovenous Fistula Embolization in Suspected Parauterine Choriocarcinoma. Case Rep Obstet Gynecol. 2016;2016:6353471. doi: 10.1155/2016/6353471. Epub 2016 Jun 14. PMID: 27403360; PMCID: PMC4923520.
Copy Download .nbib Format: NLM
Cataloging antineoplastic agents according to their effectiveness against platinum-resistant and platinum-sensitive ovarian carcinoma cell lines.

Journal of translational science

Ishiguro K, Zhu YL, Lin ZP, Penketh PG, Shyam K, Zhu R, Baumann RP, Sartorelli AC, Rutherford TJ, Ratner ES.
PMID: 27076919
J Transl Sci. 2016;2(2):117-124. doi: 10.15761/JTS.1000127. Epub 2016 Mar 05.

Although epithelial ovarian cancers (EOCs) are initially treated with platinum-based chemotherapy, EOCs vary in platinum responsiveness. Cataloging antineoplastic agents according to their effectiveness against platinum-resistant and platinum-sensitive EOC cell lines is valuable for development of therapeutic strategies to avoid...

Cite
Ishiguro K, Zhu YL, Lin ZP, et al. Cataloging antineoplastic agents according to their effectiveness against platinum-resistant and platinum-sensitive ovarian carcinoma cell lines. J Transl Sci. 2016;2(2):117-124doi: 10.15761/JTS.1000127.
Ishiguro, K., Zhu, Y. L., Lin, Z. P., Penketh, P. G., Shyam, K., Zhu, R., Baumann, R. P., Sartorelli, A. C., Rutherford, T. J., & Ratner, E. S. (2016). Cataloging antineoplastic agents according to their effectiveness against platinum-resistant and platinum-sensitive ovarian carcinoma cell lines. Journal of translational science, 2(2), 117-124. https://doi.org/10.15761/JTS.1000127
Ishiguro, Kimiko, et al. "Cataloging antineoplastic agents according to their effectiveness against platinum-resistant and platinum-sensitive ovarian carcinoma cell lines." Journal of translational science vol. 2,2 (2016): 117-124. doi: https://doi.org/10.15761/JTS.1000127
Ishiguro K, Zhu YL, Lin ZP, Penketh PG, Shyam K, Zhu R, Baumann RP, Sartorelli AC, Rutherford TJ, Ratner ES. Cataloging antineoplastic agents according to their effectiveness against platinum-resistant and platinum-sensitive ovarian carcinoma cell lines. J Transl Sci. 2016;2(2):117-124. doi: 10.15761/JTS.1000127. Epub 2016 Mar 05. PMID: 27076919; PMCID: PMC4827869.
Copy Download .nbib Format: NLM
Second-Line Therapy of Small-Cell Lung Cancer: Topotecan Compared to a Combination Treatment with Adriamycin, Cyclophosphamide And Vincristine (ACO) - a Single Center Experience.

Journal of Cancer

Hagmann R, Hess V, Zippelius A, Rothschild SI.
PMID: 26516363
J Cancer. 2015 Sep 15;6(11):1148-54. doi: 10.7150/jca.13080. eCollection 2015.

BACKGROUND: Randomized trials established topotecan and the combination of adriamycin, cyclophosphamide and vincristine (ACO) as second-line therapy options for small-cell lung cancer. We retrospectively evaluated the outcome of SCLC patients undergoing second-line chemotherapy.PATIENTS AND METHODS: 92 consecutive patients with...

Cite
Hagmann R, Hess V, Zippelius A, et al. Second-Line Therapy of Small-Cell Lung Cancer: Topotecan Compared to a Combination Treatment with Adriamycin, Cyclophosphamide And Vincristine (ACO) - a Single Center Experience. J Cancer. 2015;6(11):1148-54doi: 10.7150/jca.13080.
Hagmann, R., Hess, V., Zippelius, A., & Rothschild, S. I. (2015). Second-Line Therapy of Small-Cell Lung Cancer: Topotecan Compared to a Combination Treatment with Adriamycin, Cyclophosphamide And Vincristine (ACO) - a Single Center Experience. Journal of Cancer, 6(11), 1148-54. https://doi.org/10.7150/jca.13080
Hagmann, Raphael, et al. "Second-Line Therapy of Small-Cell Lung Cancer: Topotecan Compared to a Combination Treatment with Adriamycin, Cyclophosphamide And Vincristine (ACO) - a Single Center Experience." Journal of Cancer vol. 6,11 (2015): 1148-54. doi: https://doi.org/10.7150/jca.13080
Hagmann R, Hess V, Zippelius A, Rothschild SI. Second-Line Therapy of Small-Cell Lung Cancer: Topotecan Compared to a Combination Treatment with Adriamycin, Cyclophosphamide And Vincristine (ACO) - a Single Center Experience. J Cancer. 2015 Sep 15;6(11):1148-54. doi: 10.7150/jca.13080. eCollection 2015. PMID: 26516363; PMCID: PMC4615351.
Copy Download .nbib Format: NLM
Pilomatrix carcinoma of the scalp with pulmonary metastasis: A case report of a complete response to oral endoxan and etoposide.

Oncology letters

Arslan D, Gündüz S, Avci F, Merdin A, Tatli AM, Uysal M, Tural D, Başsorgun CI, Savaş B.
PMID: 24932268
Oncol Lett. 2014 Jun;7(6):1959-1961. doi: 10.3892/ol.2014.2021. Epub 2014 Apr 01.

Pilomatrix carcinoma is an extremely rare skin tumor derived from basaloid cells in the hair follicles; it often exhibits locally aggressive behavior with a tendency toward local recurrence. The average age of occurrence is 45 years, and there appears...

Cite
Arslan D, Gündüz S, Avci F, et al. Pilomatrix carcinoma of the scalp with pulmonary metastasis: A case report of a complete response to oral endoxan and etoposide. Oncol Lett. 2014;7(6):1959-1961doi: 10.3892/ol.2014.2021.
Arslan, D., Gündüz, S., Avci, F., Merdin, A., Tatli, A. M., Uysal, M., Tural, D., Başsorgun, C. I., & Savaş, B. (2014). Pilomatrix carcinoma of the scalp with pulmonary metastasis: A case report of a complete response to oral endoxan and etoposide. Oncology letters, 7(6), 1959-1961. https://doi.org/10.3892/ol.2014.2021
Arslan, Deniz, et al. "Pilomatrix carcinoma of the scalp with pulmonary metastasis: A case report of a complete response to oral endoxan and etoposide." Oncology letters vol. 7,6 (2014): 1959-1961. doi: https://doi.org/10.3892/ol.2014.2021
Arslan D, Gündüz S, Avci F, Merdin A, Tatli AM, Uysal M, Tural D, Başsorgun CI, Savaş B. Pilomatrix carcinoma of the scalp with pulmonary metastasis: A case report of a complete response to oral endoxan and etoposide. Oncol Lett. 2014 Jun;7(6):1959-1961. doi: 10.3892/ol.2014.2021. Epub 2014 Apr 01. PMID: 24932268; PMCID: PMC4049690.
Copy Download .nbib Format: NLM
Multidisciplinary treatment including systemic chemotherapy for a malignant phyllodes tumour of the prostate.

Canadian Urological Association journal = Journal de l'Association des urologues du Canada

Murakami Y, Tabata K, Sugita A, Mochizuki K, Maeyama R, Okazaki M, Nishi M, Matsumoto K, Fujita T, Satoh T, Jiang SX, Saegusa M, Iwamura M.
PMID: 24839496
Can Urol Assoc J. 2014 Mar;8(3):E263-5. doi: 10.5489/cuaj.1648.

A 22-year-old man was referred to our hospital with macroscopic hematuria and consistent anal pain. Magnetic resonance imaging revealed an enlarged prostate tumour invading the bladder and rectum. A biopsy revealed an unclassified spindle cell sarcoma. Subsequently, radical cystoprostatectomy...

Cite
Murakami Y, Tabata K, Sugita A, et al. Multidisciplinary treatment including systemic chemotherapy for a malignant phyllodes tumour of the prostate. Can Urol Assoc J. 2014;8(3):E263-5doi: 10.5489/cuaj.1648.
Murakami, Y., Tabata, K., Sugita, A., Mochizuki, K., Maeyama, R., Okazaki, M., Nishi, M., Matsumoto, K., Fujita, T., Satoh, T., Jiang, S. X., Saegusa, M., & Iwamura, M. (2014). Multidisciplinary treatment including systemic chemotherapy for a malignant phyllodes tumour of the prostate. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 8(3), E263-5. https://doi.org/10.5489/cuaj.1648
Murakami, Yasukiyo, et al. "Multidisciplinary treatment including systemic chemotherapy for a malignant phyllodes tumour of the prostate." Canadian Urological Association journal = Journal de l'Association des urologues du Canada vol. 8,3 (2014): E263-5. doi: https://doi.org/10.5489/cuaj.1648
Murakami Y, Tabata K, Sugita A, Mochizuki K, Maeyama R, Okazaki M, Nishi M, Matsumoto K, Fujita T, Satoh T, Jiang SX, Saegusa M, Iwamura M. Multidisciplinary treatment including systemic chemotherapy for a malignant phyllodes tumour of the prostate. Can Urol Assoc J. 2014 Mar;8(3):E263-5. doi: 10.5489/cuaj.1648. PMID: 24839496; PMCID: PMC4001657.
Copy Download .nbib Format: NLM
High grade primitive neuroectodermal tumor of the uterus: A case report.

Gynecologic oncology case reports

Dizon AM, Kilgore LC, Grindstaff A, Winkler M, Kimball KJ.
PMID: 24624321
Gynecol Oncol Case Rep. 2013 Oct 19;7:10-2. doi: 10.1016/j.gynor.2013.10.002. eCollection 2014 Jan.

•Primitive neuroectodermal tumor of the uterus is extremely rare.•Diagnosis requires timely evaluation with molecular analysis.•Different combinations of adjuvant chemotherapy have been reported.

Cite
Dizon AM, Kilgore LC, Grindstaff A, et al. High grade primitive neuroectodermal tumor of the uterus: A case report. Gynecol Oncol Case Rep. 2013;7:10-2doi: 10.1016/j.gynor.2013.10.002.
Dizon, A. M., Kilgore, L. C., Grindstaff, A., Winkler, M., & Kimball, K. J. (2014). High grade primitive neuroectodermal tumor of the uterus: A case report. Gynecologic oncology case reports, 710-2. https://doi.org/10.1016/j.gynor.2013.10.002
Dizon, A Mitch, et al. "High grade primitive neuroectodermal tumor of the uterus: A case report." Gynecologic oncology case reports vol. 7 (2014): 10-2. doi: https://doi.org/10.1016/j.gynor.2013.10.002
Dizon AM, Kilgore LC, Grindstaff A, Winkler M, Kimball KJ. High grade primitive neuroectodermal tumor of the uterus: A case report. Gynecol Oncol Case Rep. 2013 Oct 19;7:10-2. doi: 10.1016/j.gynor.2013.10.002. eCollection 2014 Jan. PMID: 24624321; PMCID: PMC3895281.
Copy Download .nbib Format: NLM
Chemosensitivity of anaplastic thyroid cancer based on a histoculture drug response assay.

International journal of endocrinology

Uruno T, Masaki C, Akaishi J, Matsuzu K, Suzuki A, Ohkuwa K, Shibuya H, Kitagawa W, Nagahama M, Sugino K, Ito K.
PMID: 25866510
Int J Endocrinol. 2015;2015:967286. doi: 10.1155/2015/967286. Epub 2015 Mar 18.

The chemosensitivity of anaplastic thyroid cancer (ATC) to some cytotoxic agents was investigated by the histoculture drug response assay (HDRA). Thirty specimens from 22 patients with ATC were obtained from surgically resected subjects. The drugs tested were paclitaxel (PTX),...

Cite
Uruno T, Masaki C, Akaishi J, et al. Chemosensitivity of anaplastic thyroid cancer based on a histoculture drug response assay. Int J Endocrinol. 2015;2015:967286doi: 10.1155/2015/967286.
Uruno, T., Masaki, C., Akaishi, J., Matsuzu, K., Suzuki, A., Ohkuwa, K., Shibuya, H., Kitagawa, W., Nagahama, M., Sugino, K., & Ito, K. (2015). Chemosensitivity of anaplastic thyroid cancer based on a histoculture drug response assay. International journal of endocrinology, 2015967286. https://doi.org/10.1155/2015/967286
Uruno, Takashi, et al. "Chemosensitivity of anaplastic thyroid cancer based on a histoculture drug response assay." International journal of endocrinology vol. 2015 (2015): 967286. doi: https://doi.org/10.1155/2015/967286
Uruno T, Masaki C, Akaishi J, Matsuzu K, Suzuki A, Ohkuwa K, Shibuya H, Kitagawa W, Nagahama M, Sugino K, Ito K. Chemosensitivity of anaplastic thyroid cancer based on a histoculture drug response assay. Int J Endocrinol. 2015;2015:967286. doi: 10.1155/2015/967286. Epub 2015 Mar 18. PMID: 25866510; PMCID: PMC4381728.
Copy Download .nbib Format: NLM
CEPP regimen (cyclophosphamide, etoposide, procarbazine and prednisone) as initial treatment for Hodgkin lymphoma patients presenting with severe abnormal liver function.

Biomarker research

Thakar K, Novero A, Das A, Lisinschi A, Mehta B, Ahmed T, Liu D.
PMID: 24991411
Biomark Res. 2014 Jun 23;2:12. doi: 10.1186/2050-7771-2-12. eCollection 2014.

ABVD regimen (doxorubicin, bleomycin, vinblastine and dacarbazine) remains the most commonly used front-line therapy for Hodgkin lymphoma. However, atypical and extranodal presentations present challenges to initial therapy, especially in the presence of renal and liver failure. We hereby present...

Cite
Thakar K, Novero A, Das A, et al. CEPP regimen (cyclophosphamide, etoposide, procarbazine and prednisone) as initial treatment for Hodgkin lymphoma patients presenting with severe abnormal liver function. Biomark Res. 2014;2:12doi: 10.1186/2050-7771-2-12.
Thakar, K., Novero, A., Das, A., Lisinschi, A., Mehta, B., Ahmed, T., & Liu, D. (2014). CEPP regimen (cyclophosphamide, etoposide, procarbazine and prednisone) as initial treatment for Hodgkin lymphoma patients presenting with severe abnormal liver function. Biomarker research, 212. https://doi.org/10.1186/2050-7771-2-12
Thakar, Keyur, et al. "CEPP regimen (cyclophosphamide, etoposide, procarbazine and prednisone) as initial treatment for Hodgkin lymphoma patients presenting with severe abnormal liver function." Biomarker research vol. 2 (2014): 12. doi: https://doi.org/10.1186/2050-7771-2-12
Thakar K, Novero A, Das A, Lisinschi A, Mehta B, Ahmed T, Liu D. CEPP regimen (cyclophosphamide, etoposide, procarbazine and prednisone) as initial treatment for Hodgkin lymphoma patients presenting with severe abnormal liver function. Biomark Res. 2014 Jun 23;2:12. doi: 10.1186/2050-7771-2-12. eCollection 2014. PMID: 24991411; PMCID: PMC4078319.
Copy Download .nbib Format: NLM
Enhanced tumor uptake, biodistribution and pharmacokinetics of etoposide loaded nanoparticles in Dalton's lymphoma tumor bearing mice.

Journal of pharmacy & bioallied sciences

Snehalatha M, Kolachina V, Saha RN, Babbar AK, Sharma N, Sharma RK.
PMID: 24302837
J Pharm Bioallied Sci. 2013 Oct;5(4):290-7. doi: 10.4103/0975-7406.120081.

BACKGROUND: Nanotechnology plays a remarkable role in the field of the treatment of Lymphomas associated with tumor.OBJECTIVE: The purpose of this study is to determine and to compare the tumor uptake, biodistribution and pharmacokinetics of radiolabeled etoposide and etoposide...

Cite
Snehalatha M, Kolachina V, Saha RN, et al. Enhanced tumor uptake, biodistribution and pharmacokinetics of etoposide loaded nanoparticles in Dalton's lymphoma tumor bearing mice. J Pharm Bioallied Sci. 2013;5(4):290-7doi: 10.4103/0975-7406.120081.
Snehalatha, M., Kolachina, V., Saha, R. N., Babbar, A. K., Sharma, N., & Sharma, R. K. (2013). Enhanced tumor uptake, biodistribution and pharmacokinetics of etoposide loaded nanoparticles in Dalton's lymphoma tumor bearing mice. Journal of pharmacy & bioallied sciences, 5(4), 290-7. https://doi.org/10.4103/0975-7406.120081
Snehalatha, Movva, et al. "Enhanced tumor uptake, biodistribution and pharmacokinetics of etoposide loaded nanoparticles in Dalton's lymphoma tumor bearing mice." Journal of pharmacy & bioallied sciences vol. 5,4 (2013): 290-7. doi: https://doi.org/10.4103/0975-7406.120081
Snehalatha M, Kolachina V, Saha RN, Babbar AK, Sharma N, Sharma RK. Enhanced tumor uptake, biodistribution and pharmacokinetics of etoposide loaded nanoparticles in Dalton's lymphoma tumor bearing mice. J Pharm Bioallied Sci. 2013 Oct;5(4):290-7. doi: 10.4103/0975-7406.120081. PMID: 24302837; PMCID: PMC3831742.
Copy Download .nbib Format: NLM
Oral Etoposide, Ifosfamide and Cisplatin in the Treatment of Extensive Disease Small Cell Lung Cancer.

Cancer research and treatment

Kim SJ, Sung HJ, Park KH, Yoon SY, Oh SC, Seo JH, Choi CW, Kim BS, Shin SW, Kim YH, Kim KT, Choi YH, Kim JS.
PMID: 26680898
Cancer Res Treat. 2002 Dec;34(6):421-5. doi: 10.4143/crt.2002.34.6.421.

PURPOSE: The combination of cisplatin and etoposide has been a common first line regimen for the treatment of small cell lung cancer (SCLC). The schedule dependence, and equal efficacy, of the oral and intravenous dosing of etoposide has led...

Cite
Kim SJ, Sung HJ, Park KH, et al. Oral Etoposide, Ifosfamide and Cisplatin in the Treatment of Extensive Disease Small Cell Lung Cancer. Cancer Res Treat. 2002;34(6):421-5doi: 10.4143/crt.2002.34.6.421.
Kim, S. J., Sung, H. J., Park, K. H., Yoon, S. Y., Oh, S. C., Seo, J. H., Choi, C. W., Kim, B. S., Shin, S. W., Kim, Y. H., Kim, K. T., Choi, Y. H., & Kim, J. S. (2002). Oral Etoposide, Ifosfamide and Cisplatin in the Treatment of Extensive Disease Small Cell Lung Cancer. Cancer research and treatment, 34(6), 421-5. https://doi.org/10.4143/crt.2002.34.6.421
Kim, Seok Jin, et al. "Oral Etoposide, Ifosfamide and Cisplatin in the Treatment of Extensive Disease Small Cell Lung Cancer." Cancer research and treatment vol. 34,6 (2002): 421-5. doi: https://doi.org/10.4143/crt.2002.34.6.421
Kim SJ, Sung HJ, Park KH, Yoon SY, Oh SC, Seo JH, Choi CW, Kim BS, Shin SW, Kim YH, Kim KT, Choi YH, Kim JS. Oral Etoposide, Ifosfamide and Cisplatin in the Treatment of Extensive Disease Small Cell Lung Cancer. Cancer Res Treat. 2002 Dec;34(6):421-5. doi: 10.4143/crt.2002.34.6.421. PMID: 26680898.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 1811 entries